471. Prevalence and characteristics of Clostridioides difficile infection in Bangladesh
Session: Poster Abstract Session: Healthcare Epidemiology: Updates in C. difficile
Thursday, October 4, 2018
Room: S Poster Hall
Posters
  • CDI Bangladesh poster v1 3 by 5.pdf (220.9 kB)
  • Background: The estimated prevalence of Clostridioides difficile infection (CDI) in several South Asian countries is 10.5%, similar to that in North America and Europe. However, the epidemiology of CDI in Bangladesh is unknown. We aimed to assess the prevalence of CDI and assess hospital environmental contamination of toxigenic C. difficile in Bangladesh.

    Methods: This was a prospective observational cohort study at two large tertiary care centers in Dhaka, Bangladesh, conducted from 01/2017 to 12/2017. Stool samples were collected from hospitalized adults with diarrhea (≥3 loose stools in a 24-hour period) and antimicrobial exposure within the past 30 days. Hospital environmental samples were collected by swabbing surfaces of common areas in the hospital. All samples underwent toxigenic culture. C. difficile isolates were tested for toxins A and B and PCR-ribotyped.

    Results: Of 204 stool samples collected, 16 (7.8%) were positive for toxigenic C. difficile. Patients with CDI shared a room with significantly more patients (Table 1). Of 392 environmental samples, 48 (12.2%) were positive for toxigenic C. difficile, which was more common in patient care versus non-patient care areas (14.4% vs 7.8%, p = 0.057). Twelve clinical stool isolates and 42 environmental isolates were ribotyped. Ribotypes identified in stool isolates were F017 (50%), FP053-163 (17%), FP435 (17%), F106 (8%), and F014-020 (8%). With the exception of FP435, these were also the most common ribotypes in environmental isolates: F017 (24%), FP053-163 (12%), F106 (26%), and F014-020 (10%).

    Conclusion: For the first time, we report the prevalence of CDI and ribotypes in at risk patients in Bangladesh. Rates and ribotypes are similar to other resource-rich or resource-limited countries.

    Table 1. Demographic data for all stool samples
    Variable No toxigenic C. difficile (n=188) Toxigenic C. difficile (n=16) p
    Female sex, n (%) 77 (41) 9 (56) 0.234
    Age, years, median (IQR) 46 (32-58) 39 (25-53) 0.212
    Hospital A, n (%) 149 (79) 13 (81) >0.99
    Length of prior hospital stay, days, median (IQR) 13 (7-23) 14 (8-32) 0.798
    Duration of previous antibiotics, days, median (IQR) 10 (7-17) 12 (6-20) 0.687
    Number of patients in the same room, median (IQR) 13 (7-19) 19 (14-20) 0.009

    Amelia K. Sofjan, PharmD1, M. Jahangir Alam, PhD1, M. Aminul Islam, PhD2 and Kevin W. Garey, PharmD, M.S.3, (1)University of Houston College of Pharmacy, Houston, TX, (2)The International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh, (3)Pptr, University of Houston College of Pharmacy, Houston, TX

    Disclosures:

    A. K. Sofjan, None

    M. J. Alam, None

    M. A. Islam, None

    K. W. Garey, Merck & Co.: Grant Investigator , Grant recipient .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.